Dietary Sodium and Inhibition of Neutral Endopeptidase 24.11 in Essential Hypertension

No abstract is available for this paper.

• Publication year

  1991

• Venue

  HYPERTENSION

• Publication date

  1991-12-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1161/01.HYP.18.6.798PMID 1835959
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Inhibition of endopeptidase EC 24.11 in humans. Renal and endocrine effects.

  1990cited by this paper
• Three peptides from the ANF prohormone NH(2)-terminus are natriuretic and/or kaliuretic.

  1990cited by this paper
• Immunoreactive N-terminal pro-atrial natriuretic peptide in human plasma: plasma levels and comparisons with alpha-human atrial natriuretic peptide in normal subjects, patients with essential hypertension, cardiac transplant and chronic renal failure.

  1989cited by this paper
• Atrial Natriuretic Factor in Hypertension: Bioactivity at Normal Plasma Levels

  1989cited by this paper
• Inhibition of ANP Degradation by the Atriopeptidase Inhibitor UK 69,578 in Normal Man

  1989cited by this paper
• UK-69,578, a novel inhibitor of EC 3.4.24.11 which increases endogenous ANF levels and is natriuretic and diuretic.

  1989influential reference
• Neutral endopeptidase 24.11 (enkephalinase) and related regulators of peptide hormones 1

  1989cited by this paper
• Prolonged decrease in blood pressure after atrial natriuretic peptide infusion in essential hypertension: a new anti-pressor mechanism?

  1989cited by this paper
• Low dose infusions of 26- and 28-amino acid human atrial natriuretic peptides in normal man.

  1988cited by this paper
• Plasma atrial natriuretic peptide in essential hypertension. Comparison with normotensive subjects and effects of changes in dietary sodium intake.

  1988influential reference
• Low dose infusion of atrial natriuretic peptide causes salt and water excretion in normal man.

  1988cited by this paper
• Effects of angiotensin II and atrial natriuretic peptide alone and in combination on urinary water and electrolyte excretion in man.

  1988cited by this paper
• Effects of Atrial Natriuretic Factor on Natriuresis and cGMP in Patients with Essential Hypertension

  1987cited by this paper
• Plasma atrial natriuretic peptide in essential hypertension: effects of changes in dietary sodium.

  1987cited by this paper
• Atrial natriuretic peptide inhibits angiotensin-stimulated proximal tubular sodium and water reabsorption

  1987cited by this paper
• Atrial natriuretic peptide: evidence of action as a natriuretic hormone at physiological plasma concentrations in man.

  1987cited by this paper
• Antihypertensive and hypotensive effects of atrial natriuretic factor in men.

  1987cited by this paper
• Effect of physiological levels of atrial natriuretic peptide on hormone secretion: inhibition of angiotensin-induced aldosterone secretion and renin release in normal man.

  1987cited by this paper
• Dose-dependent effect of atrial natriuretic peptide on blood pressure, heart rate, and skin blood flow of normal volunteers.

  1986cited by this paper
• Atrial natriuretic peptide inhibits the aldosterone response to angiotensin II in man.

  1986cited by this paper
• Sodium Loading and Posture Modulate Human Atrial Natriuretic Factor Plasma Levels

  1986cited by this paper
• Effect of human atrial natriuretic peptide on blood pressure after sodium depletion in essential hypertension.

  1986cited by this paper
• The Renal Response to Acute Hypervolemia is Caused by Atrial Natriuretic Peptides

  1986cited by this paper
• Plasma levels of immunoreactive atrial natriuretic factor in healthy subjects and in patients with edema.

  1985cited by this paper
• Atrial natriuretic factor in human blood.

  1985cited by this paper
• Effects of changes in dietary sodium intake and saline infusion on immunoreactive atrial natriuretic peptide in human plasma.

  1985cited by this paper
• Dahl's hypothesis that a saluretic substance may be responsible for a sustained rise in arterial pressure: its possible role in essential hypertension.

  1980cited by this paper
• Measurement of plasma renin activity by radioimmunoassay after prolonged cold storage.

  1978cited by this paper
• Clinical experience with use of ultrasound sphygmomanometer.

  1975cited by this paper

• Review: Update on Newer Antihypertensive Medicines and Interventions

  2010cites this paper
• Neutral endopeptidase inhibitors and endothelin antagonists.

  2008cites this paper
• Effects of body mass index and age on N-terminal pro brain natriuretic peptide are associated with glomerular filtration rate in chronic heart failure patients.

  2007cites this paper
• The Therapeutic Potential of Candoxatril, a Neutral Endopeptidase Inhibitor, in Humans

  2006cites this paper
• Cardiac Natriuretic Hormone System as Target for Cardiovascular Therapy

  2006cites this paper
• Neutral endopeptidase inhibitors and endothelin antagonists: why did the clinical trials not demonstrate beneficial effects?

  2005cites this paper
• NEP/ACE Inhibitors: Experimental and Clinical Aspects

  2004cites this paper
• Vasopeptidase inhibitors: will they have a role in clinical practice?

  2003cites this paper
• Pharmacokinetics and pharmacodynamics of the vasopeptidase inhibitor, omapatrilat in healthy subjects.

  2003cites this paper
• Vascular Protective Effects of Angiotensin Converting Enzyme Inhibitors and their Relation to Clinical Events

  2001cites this paper
• Atrial natriuretic peptide mimetics and vasopeptidase inhibitors.

  2001cites this paper
• Vasopeptidase Inhibitors: A New Class of Drugs

  2001cites this paper
• Vasopeptidase inhibitors, neutral endopeptidase inhibitors, and dual inhibitors of angiotensin-converting enzyme and neutral endopeptidase.

  2001cites this paper
• Practical implications of current natriuretic peptide research

  2000cites this paper
• Antihypertensive effects of fasidotril, a dual inhibitor of neprilysin and angiotensin-converting enzyme, in rats and humans.

  2000cites this paper
• Vasopeptidase Inhibition and its Role in Congestive Heart Failure

  2000cites this paper
• Pharmacotherapy in congestive heart failure: Vasopeptidase inhibition and its role in congestive heart failure.

  2000cites this paper
• The Role of Nitric Oxide and Kinin on the Renal Water-Sodium Metabolism

  1999cites this paper
• Pharmacology and cardiovascular implications of the kinin-kallikrein system.

  1999cites this paper
• Recent Advances in Nitric Oxide Research

  1999cites this paper
• Pharmacodynamic effects of dual neutral endopeptidase–angiotensin‐converting enzyme inhibition versus angiotensin‐converting enzyme inhibition in humans

  1999cites this paper
• Enhanced natriuretic response to neutral endopeptidase inhibition in heart-transplant recipients.

  1999cites this paper
• How does treatment influence endocrine mechanisms in acute severe heart failure? Effects on cardiac natriuretic peptides, the renin system, neuropeptide Y and catecholamines.

  1998cites this paper
• Inhibition of neutral endopeptidase causes vasoconstriction of human resistance vessels in vivo.

  1998cites this paper
• Combined inhibition of neutral endopeptidase and angiotensin‐converting enzyme by sampatrilat in essential hypertension

  1998cites this paper
• Increased tissue neutral endopeptidase 24.11 activity in spontaneously hypertensive hamsters.

  1998cites this paper
• Neutral endopeptidase inhibition potentiates the effects of natriuretic peptides in renin transgenic rats.

  1996cites this paper
• Acute and chronic neutral endopeptidase inhibition in rats with aortocaval shunt.

  1996cites this paper
• Renal response to candoxatrilat in patients with heart failure.

  1995cites this paper
• Hormonal and renal responses to neutral endopeptidase inhibition in normal humans on a low and on a high sodium intake

  1995cites this paper
• Interaction of a neutral endopeptidase inhibitor with an ANP-C receptor ligand in anesthetized dogs.

  1995cites this paper
• Comparison of candoxatril and atrial natriuretic factor in healthy men. Effects on hemodynamics, sympathetic activity, heart rate variability, and endothelin.

  1995cites this paper
• Experimental Hypertension and Therapeutic Progress: Vasodilation and Beyond

  1995cites this paper
• Clinical Relevance of Atrial Natriuretic Peptide

  1995cites this paper
• The role of kinins and atrial natriuretic peptide on the renal effects of neutral endopeptidase inhibitor in normotensive and hypertensive rats.

  1995cites this paper
• The mechanisms of the renal effects of neutral endopeptidase inhibitor in rats.

  1995cites this paper
• The natriuretic peptides and hypertension

  1994cites this paper
• Blood pressure and endocrine responses to changes in dietary sodium intake in cardiac transplant recipients. Implications for the control of sodium balance.

  1994cites this paper
• Evidence for a new role of natriuretic peptides: control of intraocular pressure.

  1994cites this paper
• Atrial Natriuretic Peptide and Its Potential Role in Pharmacotherapy

  1994cites this paper
• SODIUM LOADS ENHANCE THE NATRIURETIC RESPONSES TO ATRIAL NATRIURETIC PEPTIDE AND NEUTRAL ENDOPEPTIDASE INHIBITORS IN CONSCIOUS CYNOMOLGUS MONKEYS

  1994cites this paper
• Brain and atrial natriuretic peptides: a dual peptide system of potential importance in sodium balance and blood pressure regulation in patients with essential hypertension

  1994cites this paper
• N-terminal atrial natriuretic peptide and atrial natriuretic peptide in human plasma: investigation of plasma levels and molecular circulating form(s) using radioimmunoassays for pro-atrial natriuretic peptide (31-67), pro-atrial natriuretic peptide (1-30) and atrial natriuretic peptide (99-126).

  1994cites this paper
• The role of kinins and atrial natriuretic peptide on the renal effects of neutral endopeptidase inhibitor in rats.

  1994cites this paper
• Atrial natriuretic peptide. An overview of clinical pharmacology and pharmacokinetics.

  1993cites this paper
• Chronic inhibition of endopeptidase 24.11 in essential hypertension: evidence for enhanced atrial natriuretic peptide and angiotensin II

  1993cites this paper
• On the role of atrial natriuretic factor in normotensive and hypertensive man. With special emphasis on lithium clearance in the assessment of renal tubular sodium handling.

  1993cites this paper
• The natriuretic peptide family: turning hormones into drugs.

  1993cites this paper
• Clinical potential of endopeptidase-24.11 inhibitors in cardiovascular disease.

  1993cites this paper
• The Effect of Antihypertensive Treatment on the Quality of Later Years

  1993cites this paper
• Inhibition of endopeptidase EC 3.4.24.11 by candoxatril lowered blood pressure and increased urinary but not plasma atrial natriuretic peptide in essential hypertension

  1993cites this paper
• Endopeptidase-24.11 and its inhibitors: potential therapeutic agents for edematous disorders and hypertension.

  1993cites this paper
• Endopeptidase 24.11 inhibition by SCH 42495 in essential hypertension.

  1993cites this paper
• Atrial Natriuretic Peptide

  1993cites this paper
• Plasma brain natriuretic peptide and endopeptidase 24.11 inhibition in hypertension.

  1993cites this paper
• Acute Inhibition of Endopeptidase 24.11 in Essential Hypertension: SCH 34826 Enhances Atrial Natriuretic Peptide and Natriuresis Without Lowering Blood Pressure

  1992cites this paper
• Atrial natriuretic peptide: synthesis, release, and metabolism.

  1992cites this paper